



Republic of the Philippines  
Department of Health

## CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2018-220-A

30 May 2018

### RECOMMENDING APPROVAL OF THE AWARD OF CONTRACT FOR ITEM NO. 2 FOR THE PROCUREMENT OF CISPLATIN IB NO. 2018-165

WHEREAS, Open Competitive Bidding for the Procurement of Cisplatin was conducted in accordance with Republic Act (RA) 9184 and its 2016 Implementing Rules and Regulations (IRR) with a Total Approved Budget for the Contract (ABC) of **One Million Three Hundred Sixty Thousand Five Hundred Forty Five Philippine Pesos (Php1,360,545.00)**;

Item No.	Description	Qty.	Unit	Total ABC (Php)
1	Cisplatin 10mg	850	Vial	124,695.00
2	Cisplatin 50mg	2,100	Vial	1,235,850.00
TOTAL				1,360,545.00

WHEREAS, on 02 February 2018, the Central Office Bids and Awards Committee (COBAC)-A received Purchase Requests (PRs) from Disease Prevention and Control Bureau- Lifestyle Related Diseases Division (DPCB-LRDD);

WHEREAS, on 09 February 2018, a Pre-procurement Conference took place as scheduled at 9:00 A.M at the COBAC Conference Room, Department of Health (DOH), to determine the readiness of the procurement at hand;

WHEREAS, on 12 February 2018, the COBAC-A issued a memorandum to the End-user, DPCB-LRDD, requesting confirmation on the comments/suggestion made during the Pre-procurement Conference;

WHEREAS, on 13 February 2018, a response from DPCB-LRDD was received and informing that the revised PRs were already forwarded to Pharmaceutical Division (PD) for clearance;

WHEREAS, on 20 February 2018, a revised PRs were received and reflecting the changes on the ABC;

WHEREAS, on 22 and 28 of February 2018, the COBAC-A issued memoranda to DPCB-LRDD following-up the submission of Allocation List;

WHEREAS, on 28 February 2018, Allocation List was received;

WHEREAS, on 05 March 2018, the Invitation to Bid was published and posted in the PhilGEPS Website and other conspicuous places within the premises of the DOH. The advertisement of the IB in a newspaper of general nationwide circulation provided in Section 21.2.1 (c) of the 2016 IRR of RA 9184 shall not be required for contracts to be bid with an approved budget of Php10M and below for the procurement of goods;

WHEREAS, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2018-113 dated 06 March 2018;

WHEREAS, on 13 March 2018, a Pre-bidding Conference took place as scheduled at 10:00 A.M. at the COBAC Conference Room, DOH, with four (4) prospective bidders attending, namely:

1. Metro Drug, Inc. (MDI);
2. Zaelling Pharma Corp. (ZPC);
3. Medethix, Inc. (MD); and,
4. United Laboratories, Inc. (ULI).

WHEREAS, on 14 March 2018, the COBAC-A issued a memorandum to DPCB-LRDD, requesting confirmation on the comments/suggestion made during the Pre-bidding Conference;

WHEREAS, on 20 March 2018, the COBAC-A issued a memorandum following-up the submission of the revised PRs;

WHEREAS, a Bid Bulletin No. 1, dated 21 March 2018 was issued to announce the postponement for the Submission and Opening of Bids previously stated on 27 March 2018;

WHEREAS, a Bid Bulletin No. 2, dated 26 March 2018 was issued clarifying the issues and concerns raised during the Pre-bidding Conference and to announce the new schedule of the Submission and Opening of Bids;

**WHEREAS**, on 03 April 2018, the Submission of Bids took place as re-scheduled at 9:00 A.M. at the COBAC Conference Room, DOH;

**WHEREAS**, two (2) prospective bidders purchased the bidding documents and submitted their respective proposals, namely:

1. ZPC; and,
2. Phil Pharmawealth, Inc. (PPI).

**WHEREAS**, Notice of Change of Schedule dated 03 April 2018 was issued to announce the new schedule of the Opening of Bids from 03 April 2018 to 06 April 2018;

**WHEREAS**, the Opening of Bids took place as re-scheduled on 06 April 2018 at 9:00 A.M. at the COBAC Conference Room, DOH;

**WHEREAS**, on 14 March 2018, the COBAC-A issued a memorandum to DPCB-LRDD, requesting confirmation on the comments/suggestion made during the Pre-bidding Conference;

**WHEREAS**, on 20 March 2018, the COBAC-A issued a memorandum following-up the submission of the revised PRs;

**WHEREAS**, a Bid Bulletin No. 1, dated 21 March 2018 was issued to announce the postponement for the Submission and Opening of Bids previously slated on 27 March 2018;

**WHEREAS**, a Bid Bulletin No. 2, dated 26 March 2018 was issued clarifying the issues and concerns raised during the Pre-bidding Conference and to announce the new schedule of the Submission and Opening of Bids;

**WHEREAS**, on 03 April 2018, the Submission of Bids took place as re-scheduled at 9:00 A.M. at the COBAC Conference Room, DOH;

**WHEREAS**, two (2) prospective bidders purchased the bidding documents and submitted their respective proposals, namely:

1. ZPC; and,
2. Phil Pharmawealth, Inc. (PPI).

**WHEREAS**, Notice of Change of Schedule dated 03 April 2018 was issued to announce the new schedule of the Opening of Bids from 03 April 2018 to 06 April 2018;

**WHEREAS**, the Opening of Bids took place as re-scheduled on 06 April 2018 at 9:00 A.M. at the COBAC Conference Room, DOH;

**WHEREAS**, the first envelopes, containing the Eligibility and Technical Documents were individually opened and the presence, completeness and correctness of all the documents were individually verified by the COBAC-A in the presence of the prospective bidders' representative. Upon checking, ZPC JV with Interphil Laboratories, Inc. (ILI) was declared "INELIGIBLE" due to expired Certificate of Product Registration (CPR);

**WHEREAS**, the PPI was declared "ELIGIBLE";

**WHEREAS**, the second envelope containing the Financial Proposals of PPI was opened and the presence, completeness and correctness of the documents was verified by the COBAC-A. Upon examination, the "ELIGIBLE" bidder, PPI was rated "PASSED", and subsequently its respective proposal was read out publicly and posted in the Abstract of Bids, to wit:

					1	2
Name of Company					ZPC JV WITH INTERPHIL LABORATORIES, INC.	PPI
Bid Security					BSD	BSD
Amount					N/A	N/A
Validity					N/A	N/A
REMARKS					INELIGIBLE - EXPIRED CPR (3/3/2018)	ELIGIBLE / PASSED
Item No.	Item Description	Qty.	Unit	TOTAL ABC (Php)	BID PRICE AS READ (Php)	
1	Cisplatin 10mg	850	Vial	124,695.00	-	NO BID
2	Cisplatin 50mg	2,100	Vial	1,235,850.00	-	822,969.00
TOTAL				1,360,545.00	-	822,969.00

WHEREAS, COBAC Resolution No. 2018-220 "Declaration of Failure of Bidding for the Item No. 1 – Cisplatin 10mg for the Procurement of Cisplatin under IB No. 2018-165", was approved;

WHEREAS, PPI was declared as the Single Bidder for Item No. 2 subject to further arithmetical review and corrections of the financial bid, if necessary;

WHEREAS, the bids for the item listed below were found to be substantially complying:

Item No. 2: 2,100 vials of Cisplatin 50mg

Bidder No.	Name of Company	ABC (Php)	Bid as Calculated Amount (Php)	% Variance from ABC
2	PPI	1,235,850.00	822,969.00	33.41%

WHEREAS, on 10 April 2018, the detailed initial evaluation of the submitted proposals on the legal, technical and financial aspects of the documents of the LCB was undertaken by the designated TWG;

WHEREAS, on 30 April 2018, the TWG found PPI compliant with the bidding requirements and submitted its TWG report;

WHEREAS, the cited TWG report was presented to COBAC-A during its 18<sup>th</sup> Regular Meeting. Upon deliberation, the COBAC-A concurred with the TWG and decided to proceed with the post-qualification evaluation upon receipt of post-qualification documents;

WHEREAS, on 07 May 2018, a notification was issued to PPI, requesting for the submission of post-qualification requirements;

WHEREAS, on 09 May 2018, PPI submitted its post-qualification requirements and subsequently was forwarded to the TWG, for evaluation;

WHEREAS, on 15 May 2018, the TWG found PPI "responsive" on its post-qualification documents and submitted their post-qualification report;

WHEREAS, on 22 May 2018, the TWG Reports was presented to COBAC-A during its 20<sup>th</sup> Regular Meeting concurred with the TWG report and recommended the award of contract in favor of PPI for Item No. 2;

WHEREAS, on 28 May 2018, the TWG submitted the Bid Evaluation and Post Qualification Evaluation Reports citing PPI "responsive" on the submitted documents;

WHEREAS, the COBAC-A reviewed and deliberated the TWG reports, as well as the documents submitted by PPI. The following are the salient points of discussion:

Item No.	Description	Name of Bidder	Bidder's Rank	ABC (Php)	Bid Price (Php)	TWG		COBAC	
						Finding	Recommendation	Finding	Recommendation
2	Cisplatin 50mg	PPI	SCB	1,235,850.00	822,969.00	The SCB passed the post qualification and found to have complied with the legal, technical and financial requirements.	Responsive	• COBAC conforms with the recommendation of the TWG. • PPI is determined to be responsive and post-qualified and recommended for the award of contract for Item No. 2.	Single Calculated Responsive Bid (SCRB)

WHEREAS, at the time of the signing of this resolution, there is no pending incident, no pending Motion for Reconsideration, no pending Protest and the COBAC-A followed the requirements set forth in R.A. 9184;

NOW THEREFORE, on the basis of the above, the herein members of the COBAC-A HEREBY RESOLVES to recommend the award of contract to **Phil Pharmawealth, Inc.** determined as the SCRB with a Total Contract Price of **Eight Hundred Twenty Two Thousand Nine Hundred Sixty Nine Philippine Pesos (PhP822,969.00)** inclusive of other taxes for the item listed below:

Item No.	Particular	Qty.	Unit	Total Amount (PhP)
2	Cisplatin 50mg	2,100	Vial	822,969.00


Signed this **JUN 20 2018** 2018 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) - A

  
**LEONTA P. GORGOLON, MHA, MCHM, CEO VI**  
Regular Member

  
**FERCHITO L. AVELINO, MD, PHSAE**  
Regular Member

  
**KENNETH G. RONQUILLO, MD, MPH, MPH, CESO III**  
Vice-Chairperson

  
**MAR WYNN C. BELLO, MD, MPA**  
Regular Member

**NESTOR F. SANTIAGO, JR., MD, MPH, MHS, CESO III**  
Assistant Secretary of Health  
Chairperson

By Authority of the Secretary of Health:

  
**MYRNA C. CABOTAJE, MD, MPH, CESO III**  
Director IV  
Disease Prevention and Control Bureau  
**JUN 09 2018**